MEXILETINE FOR TREATMENT OF CHRONIC PAINFUL DIABETIC NEUROPATHY
References (20)
- et al.
Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function
Lancet
(1983) - et al.
Mechanism of pain in diabetic peripheral neuropathy
Am J Med
(1984) - et al.
Dercum's disease (adipositas dolorosa) Treatment of the severe pain with intravenous lidocaine
Pain
(1987) - et al.
The analgesic effect of tocainide in trigeminal neuralgia
Pain
(1987) Quantative determination of hemoglobin A1c by thin-layer isoelectric focusing
J Chromatogr
(1980)- et al.
The effect of systemic tocainide, lidocaine and bupivicane on nociception in the rat
Pain
(1985) - et al.
Imipramine treatment of painful diabetic neuropathy
JAMA
(1984) - et al.
Symptomatic treatment of penpheral diabetic neuropathy with Carbarnarepine (Tegretol) Double-blind, cross-over trial
Diabetologia
(1969) - et al.
Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy
Diabetes Care
(1982)
Cited by (319)
Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain?
2016, Trends in Pharmacological SciencesCitation Excerpt :Mexiletine [1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride] is a Class 1b antiarrhythmic that is structurally related to lidocaine; it blocks multiple NaV-type channels, including NaV1.2 [186], NaV1.4 [187], NaV1.5 [188], NaV1.7 [189], as well as tetrodotoxin-resistant Na+ currents (presumably mediated by NaV1.8 and/or NaV1.9; [138]) in DRG neurons [186]. Early reports suggested that orally administered mexiletine could possibly improve neuropathic pain associated with idiopathic sensorimotor polyneuropathy, chemotherapy administration, diabetes [190,191], and erythromelalgia [192,193]. Subsequent reports also suggested that oral mexiletine could improve pain symptoms in some, but perhaps not all, patients with NaV1.7-linked erythromelalgia [189,194,195].
Fentanyl produces an anti-hyperalgesic effect through the suppression of sodium channels in mice with painful diabetic neuropathy
2014, European Journal of PharmacologyCitation Excerpt :Correspondingly, the percentage of large-soma DRG neurons expressing TTX-S Nav1.2, Nav1.3, Nav1.7, and TTX-R Nav1.9 significantly increased in diabetic animals, suggesting that these alterations may underlie the increased sodium currents in diabetic rats. In fact, some sodium channel blockers, such as lidocaine and mexiletine, effectively prevent the tactile allodynia associated with diabetes-induced neuropathy under clinical diabetic neuropathic pain conditions (Viola et al., 2006; Wolff et al., 2010; Dejgard et al., 1988; Oskarsson et al., 1997) and in rodent models of painful diabetic neuropathy (Kamei et al., 1995; Suzuki et al., 2011). In this regard, interestingly, the sodium channel openers fenvalerate and veratridine antagonized the anti-hyperalgesic effect of fentanyl in diabetic mice, but had no effect on the antinociception induced by fentanyl in non-diabetic mice.
Considerations for neuropathic pain conditions in life care planning
2013, Physical Medicine and Rehabilitation Clinics of North AmericaDiabetic neuropathy part 1. Overview and symmetric phenotypes
2013, Neurologic ClinicsIn vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice
2023, Recent Advances in Inflammation and Allergy Drug Discovery